Jefferies raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $225 from $185 and keeps a Buy rating on the shares. The HERIZON-GEA trial evaluating Ziihera showed efficacy against adenocarcinoma, with the data hitting the firm’s bull case, the analyst tells investors in a research note. The firm overall expects Zani will be standard of care in 1L GEA and sees an expansion opportunity.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Jazz Pharmaceuticals rises 20.6%
- Jazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital
- Promising Phase 3 Trial Results and Expanding Indications Drive Buy Rating for Jazz Pharmaceuticals
- Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley